BACKGROUND/OBJECTIVES: Little information is available regarding the interactions of sarcopenia and metabolic syndrome (MetS) in the risks of these age-associated diseases in women. The present cross-sectional study was performed to investigate whether the coexistence of sarcopenia and MetS further increases the risks of lifestyle-related diseases in Japanese women. SUBJECTS/METHODS: Healthy Japanese women (n ¼ 533) aged 30-84 participated in this study. MetS was defined as higher body mass index, fasting plasma glucose, systolic or diastolic blood pressure and blood lipid abnormalities. Appendicular muscle mass and bone mineral density (BMD) were measured using dual-energy X-ray absorptiometry. The criterion of low muscle mass and strength defined median skeletal muscle index (appendicular muscle mass/height 2 , kg/m 2 ) and handgrip strength. RESULTS: Two-way ANCOVA with adjustment for age, body fat percentage and whole-body lean tissue mass indicated that sarcopenia and MetS interacted to produce a significant effect on HbA1c, systolic blood pressure, triglycerides and brachial-ankle pulse wave velocity in Japanese women. The systolic blood pressure, triglycerides and brachial-ankle pulse wave velocity were significantly higher in women with coexisting sarcopenia and MetS than in healthy controls or in those with sarcopenia or MetS alone. The HbA1c in the coexisting sarcopenia and MetS group was higher than in healthy controls and sarcopenia subjects. CONCLUSIONS: The coexistence of sarcopenia and MetS further increases the risks of cardiovascular diseases, such as type 2 diabetes mellitus, hypertension, arterial stiffness and hyperlipidemia even adjustment of age and body composition in adult Japanese women.
INTRODUCTION
Sarcopenia, a reduction in muscle mass and muscle strength with age, causes impaired gait, 1 disability, 2 falls 3 and osteoporosis, [4] [5] [6] and increases the risk of developing a wide range of chronic disorders, including hypercholesterolemia, atherosclerosis, hyperglycemia, insulin resistance and hypertension. [7] [8] [9] [10] On the other hand, it is well known that metabolic syndrome (MetS), which generally increases with advancing age, is also associated with increased risk of vascular events, 11 ischemic stroke 12 and type 2 diabetes mellitus. 13 Although the causes of sarcopenia are not yet clearly understood, catabolic stimulation (subclinical inflammation and production of catabolic cytokines) of muscle has been investigated as a potential mechanism of sarcopenia. 14 Thus, the causes of sarcopenia and MetS, which are associated with abnormal adipocytokine secretion, partly overlap. However, the interaction between sarcopenia and MetS on the risks of cardiovascular diseases (CVD) has not been investigated in detail.
Many investigators have shown that muscle strength [15] [16] [17] [18] and muscle mass 4, 19, 20 are associated with site-matched bone mineral density (BMD). Walsh et al. 4 established that the prevalence of sarcopenia was 12.5% in premenopausal osteopenic women, while in postmenopausal women, the value was 25% for those with osteopenia and 50% for those with osteoporosis. Previous studies showed that vertebral BMD was significantly lower in women with MetS among 2475 Korean women after adjustment for age, weight and height, 21 and the incidence of osteoporotic non-vertebral fractures was higher in women with MetS in the Rancho Bernardo Study. 22 Therefore, although BMD may be associated with both sarcopenia and MetS, it has not been determined whether the interaction between sarcopenia and MetS further increases total and regional BMD as determined by dual-energy X-ray absorptiometry (DXA).
We hypothesized that the coexistence of sarcopenia and MetS causes further increases in the risks of lifestyle-related diseases, including CVD and osteoporosis, in adult women. The present cross-sectional study was performed to investigate whether the coexistence of sarcopenia and MetS causes further increases in the risks of lifestyle-related diseases in adult Japanese women.
MATERIALS AND METHODS Subjects
Healthy Japanese women (n ¼ 533) aged 30-84 years participated in this study; these were the same subjects as included in our previous study. 9 The distribution of age categories of subjects were 11.4% (n ¼ 61) of o39yrs, 21.2% (n ¼ 113) of o49 yrs, 25.9% (n ¼ 138) of o59 yrs, 29.8% (n ¼ 159) of o69 yrs and 11.6% (n ¼ 62) of o85 yrs, respectively. Subjects were recruited from the community around the National Institute of Health and Nutrition (Tokyo, Japan). All subjects were free of overt CVD and stroke, as determined using a medical history questionnaire. The subjects were not taking any medications, such as beta-blockers, steroids or hormone replacement therapy. All subjects were free of any overt signs or symptoms of chronic disease. They were sedentary or moderately active, and participated in a swimming, stretching and 'healthy gymnastics' program; however, none of the subjects participated in other vigorous sports activities. The purpose, procedures and risks of the study were explained to all participants before inclusion, and all subjects gave their written informed consent before enrolling in the study. The study was performed in accordance with the guidelines of the Declaration of Helsinki and was approved by the Human Research Committee of the National Institute of Health and Nutrition, Tokyo, Japan. Body weight and height were recorded, and body mass index was calculated as weight in kilograms divided by the square of the height in meters. Systolic blood pressure, diastolic blood pressure and mean blood pressure were measured at rest using a vascular testing device (Form PWV/ABI; Colin Medical Technology, Tokyo, Japan). Chronic arterial blood pressure levels at rest were measured with the same device over the brachial and dorsalis pedis arteries. Recordings were made in triplicate with subjects in the supine position. The brachial-ankle pulse wave velocity (baPWV), which provides qualitatively similar information to that derived from central arterial stiffness, 23 was measured by the volume plethysmographic method.
Analysis of blood samples
All blood samples were drawn with the subject in the seated position. Fasting (412 h) blood samples were collected by venipuncture in tubes with or without ethylenediamine tetraacetic acid (for plasma or serum). The blood samples were centrifuged at 1500 r.p.m. for 15 min and stored at -20 1C. Serum concentrations of triglycerides were determined by commercial kits (Mitsubishi Chemical Medience, Tokyo, Japan). Serum high-density lipoprotein (HDL)-cholesterol was measured by an enzymatic method (Mitsubishi Chemical Medience). Fasting plasma glucose was measured by the glucose dehydrogenase method. Whole-blood glycohaemoglobin A1c (HbA1c) was measured by an enzymatic method (Glycohemoglobin A1c kit; Mitsubishi Chemical Medience).
As waist circumference data were not available, the following risk factors of MetS (highest value ¼ 4) were used: (1) body mass index X25 kg/m 2 ; (2) blood pressure X130 mm Hg systolic and/or X85 mm Hg diastolic; (3) triglycerides X150 mg/dl and/or HDL-cholesterol p40 mg/dl; and (4) fasting plasma glucose X110 mg/dl. The body mass index value was shown previously to be a useful predictor of the presence of multiple metabolic risk factors similar to waist circumference in middle-aged Japanese subjects. 24 The definition of MetS was high body mass index plus one or more of the other risk factors. Recently, previous studies have commonly used these criteria and definition of MetS in Japan. 25, 26 Measures of whole-body DXA Lean soft tissue mass and BMD were determined for the whole body by DXA (Hologic QDR-4500A scanner; Hologic, Waltham, MA, USA). Participants were positioned for whole-body scans in accordance with the manufacturer's protocol. Participants lay in the supine position on the DXA table with the limbs close to the body. The whole-body lean soft tissue mass was divided into several regions, that is, the arms, legs and trunk. Body composition was determined by Hologic software version 11.2:3 for windows (Hologic). A recent investigation indicated that the definition of sarcopenia was based on documentation of criterion low muscle mass plus low muscle strength. 27 Therefore, the criterion of low muscle mass defined median SMI value of 6.70 kg/m 2 in this study subjects. On the other hands, low muscle strength was defined by low handgrip strength, and the cutoff value of handgrip strength was defined as values one standard deviation (s.d.) below the mean of handgrip strength obtained in this study from younger adults aged 30-49. The mean ± s.d. of handgrip strength were 29.8 ± 5.4 and cutoff value was 24.4 kg. Previous study demonstrated o20 kg of the handgrip strength for the cutoff value. 28 In the present study, there is no information of the cutoff value of sarcopenia-involved muscle strength in Japanese population.
Measures of fitness
The maximum oxygen uptake (VO 2 max) was measured by incremental exercise testing using a cycle ergometer. Incremental cycle exercise began at a work rate of 90 W (60 r.p.m.), and power output was increased by 30 W/min until the subjects could not maintain the fixed pedaling frequency. During the ergometer test, the subjects were encouraged to exercise at as high intensity as possible. Subjects breathed through a lowresistance two-way valve, and the expired air was collected in Douglas bags. Expired O 2 and CO 2 gas concentrations were measured by mass spectrometry (WSMR-1400; Westron, Chiba, Japan), and gas volume was determined using a dry gas meter (NDS-2A-T; Shinagawa Dev., Tokyo, Japan). The highest value of VO 2 during the exercise test was designated as VO 2 max. Handgrip strength of the right upper limb was measured using a handheld dynamometer. In the standing position, with the arms straight by the sides, the subject gripped the dynamometer as hard as possible for 3 s without pressing the instrument against the body or bending at the elbow. Values (kg) were recorded as the averages of two trials. Leg extension power was measured with an isokinetic leg power system (Anaero Press 3500; Combi Wellness, Tokyo, Japan) in the sitting position. Flexibility was measured by a sit-and-reach test using a digital flexibility testing device (T.K.K.5112; Takeikiki, Tokyo, Japan) after some stretching. The device displays the distance through which it has moved. Subjects sat on the floor with their hips, back and occipital region of the head touching a wall, and the legs held straight by the tester. They placed both hands on the device with the arms held straight. The zero point of the device was set in this position. They were then asked to bend forward slowly and reach as far forward as possible. The better of two trials was recorded.
Statistical analysis
We compared the mean values of physical characteristics, body composition, fitness and the risks of lifestyle-related diseases between healthy controls and sarcopenia or MetS groups by the unpaired Student's t-test. The proportions of sarcopenia and MetS were confirmed by the w 2 test. In addition, we tested the influence of sarcopenia and MetS on the risks of lifestyle-related diseases by two-way ANCOVA with adjustment for age, body fat percentage and whole-body lean tissue mass as a covariate. When a significant difference was observed in the interaction, comparisons between groups were tested by the unpaired Student's t-test. Values are expressed as means±s.e.m. In all analyses, Po0.05 was taken to indicate statistical significance.
RESULTS
Comparisons between subjects' characteristics and MetS risks in the subjects with sarcopenia and/or MetS and healthy control subjects are shown in Table 1 . Body fat percentage was significantly higher in both sarcopenia and MetS women than in healthy controls (Po0.01). Whole-body and regional BMD in sarcopenia women were significantly lower than those in healthy controls (Po0.001). The leg extension power, handgrip strength and flexibility in sarcopenia women were significantly lower than those in healthy controls (Po0.001). The VO 2 max in MetS women were significantly lower than those in healthy controls (Po0.05).
The w 2 test indicated that the prevalence of sarcopenia was significantly higher in subjects without MetS (122/468, 26.1%) than in those with MetS (7/65, 10.8%, Po0.01). We tested the interaction of sarcopenia and MetS on subject's characteristics and MetS risks by two-way ANCOVA with adjustment for age, body fat percentage and whole-body lean tissue mass as a covariate ( Table 2 ). The effects of the interaction between sarcopenia and MetS on systolic blood pressure, baPWV and HbA1c (Figure 1 ) were significant. The systolic blood pressure and baPWV in subjects with coexisting sarcopenia and MetS were significantly higher than those in subjects with either sarcopenia or MetS alone and in healthy controls. In addition, the effects of the interaction between sarcopenia and MetS on serum triglycerides level and triglycerides/HDL-cholesterol were significant. The triglycerides and triglycerides/HDL-cholesterol in the healthy controls were significantly lower than those in subjects with both sarcopenia and MetS or in those with either sarcopenia or MetS alone ( Table 2 ). The interactions of sarcopenia and MetS on subject's body composition and fitness are shown in Table 3 . The effects of the interaction between sarcopenia and MetS on fitness and both whole-body and regional BMD were not significant.
DISCUSSION
This cross-sectional study was performed to investigate whether the coexistence of sarcopenia and MetS causes further increases in the risks of lifestyle-related diseases, including CVD and osteoporosis, in adult Japanese women. The results indicated that sarcopenia and MetS interacted to produce significant effects on CVD risks, such as systolic blood pressure, baPWV, HbA1c, serum triglycerides level and triglycerides/HDL-cholesterol. These results suggest that the coexistence of sarcopenia and MetS leads to further increases in the risks of type 2 diabetes mellitus, hypertension, arterial stiffness and hyperlipidemia even adjustment of age and body composition in adult Japanese women.
The w 2 test indicated that the prevalence of sarcopenia was significantly higher in subjects without MetS (122/468, 26.1%) than in those with MetS (7/65, 10.8%). Subjects with sarcopenia have a healthy appearance, because they are most often not undernourished. MetS is closely associated with CVD and type 2 diabetes mellitus 29 and therefore it has been the focus of governmental health promotion activities in developed countries. However, sarcopenia is less well understood among the public, although many studies have shown that sarcopenia affects disability, 2 the risk of fractures [4] [5] [6] and a wide range of chronic disorders. [7] [8] [9] [10] We confirmed that both sarcopenia and MetS are important factors that should be taking into account in governmental health promotion programs to regulate medical treatment costs.
Recently, it has been demonstrated that sarcopenia obesity is a new category of obesity in the elderly. 30 Central obesity directly affects inflammation, which in turn negatively affects muscle strength, contributing to the development and progression of sarcopenia obesity.
14 Therefore, proinflammatory cytokines may be critical in both the development and progression of sarcopenia obesity. Stephen and Janssen 31 reported that sarcopenia obesity, identified based on muscle strength but not muscle mass, was modestly associated with increased CVD risk. A community-based elderly cohort study in Korea in subjects aged 65 years or older showed that sarcopenia obesity, defined by appendicular muscle mass/body weight using DXA and visceral fat area exceeding 100 cm 2 on abdominal computed tomography, was more closely associated with MetS than either sarcopenia or obesity alone. 32 A longitudinal follow-up study of over 3000 older adults indicated that the combination of low muscle mass and abdominal obesity was not associated with an increased risk for the development of CVD over an 8-year follow-up period. 31 In addition, although the number of subjects in this study was relatively small, sarcopenic obese women have less risk factors predisposing them to CVD compared with obese postmenopausal women. 33 Thus, the results of previous studies regarding the relation between sarcopenia obesity and the risks of CVD are still controversial. Our results showed that the effects of the interaction between sarcopenia and MetS on systolic blood pressure, baPWV and HbA1c were significant ( Table 2 ). The baPWV is a recognized indicator of arterial stiffness 34 and arterial compliance 35 and has been regarded as a marker reflecting vascular damage. 36 In addition, the effects of the interaction between sarcopenia and MetS on triglycerides and triglycerides/HDL-cholesterol were also significant in this study. The serum triglycerides level and triglycerides/ HDL-cholesterol, which are indexes of atherosclerosis, were significantly lower in the healthy controls than in subjects with sarcopenia and MetS and in those with sarcopenia or MetS alone ( Table 2 ). These results indicate that it is desirable to remain without sarcopenia and MetS for the prevention of type 2 diabetes mellitus, hypertension, arterial stiffness and hyperlipidemia in adult women.
Previous studies showed that subjects with MetS had increased femoral neck BMD compared with controls without MetS in a United States population-based study, 37 and MetS women showed higher BMD than controls, mainly driven by their higher body weight, but bone remodeling was lower in these women. 38 Hernandez et al. 38 reported that despite the greater bone mass and lower bone turnover, fracture prevalence was not reduced, suggesting poorer bone quality and/or a higher tendency to fall. On the other hand, the mean vertebral BMD was significantly lower in subjects with MetS after adjustment for age, weight and height among 2475 Korean women. 21 Hwang and Choi 21 suggested that these two conflicting results may have been due to differences in subjects (race, age and comorbid disease status), adjusting covariates (especially menopause in women), samples used (non-fasting serum) and methods of analysis. Many investigators have shown that muscle strength [15] [16] [17] [18] and muscle mass 4, 19, 20 are associated with site-matched BMD. Walsh et al. reported that the prevalence rates of sarcopenia were 25% and 50% in postmenopausal women with osteopenia and with osteoporosis, respectively. 4 However, it is not clear whether the coexistence of sarcopenia and MetS causes further increases in total and regional BMD. In the present study, the effects of the interaction between sarcopenia and MetS on whole-body, arm and trunk BMD were not significant. However, there was significant difference in the whole-body and regional BMD between the normal and sarcopenia subjects but not between the normal and MetS subjects. These results suggest that the BMD in adult women has an impact on sarcopenia more than MetS. Previous studies regarding the relationship between cardiorespiratory fitness and MetS suggested that a low level of physical fitness is a strong determining factor in the prevalence of MetS. [39] [40] [41] [42] [43] Lakka et al. 41 suggested that a sedentary lifestyle and especially low cardiorespiratory fitness measured by VO 2 max are not only associated with MetS but could also be considered features of MetS. On the other hand, skeletal muscle mass directly affects to individual VO 2 max level regardless of upper and lower extremity exercise, 44 and sarcopenia is associated with age-related loss of VO 2 max among healthy people across the adult age range. 45 It is not understood how the interaction of sarcopenia and MetS causes further decreases in the age-related loss of cardiorespiratory fitness or muscle power. The results of this study showed that the effect of the interaction between sarcopenia and MetS on VO 2 max was not significant. However, there was significant difference in the VO 2 max between the normal and MetS subjects but not between the normal and sarcopenia subjects. These results suggest that the cardiorespiratory fitness in adult women has an impact on MetS more than sarcopenia.
The present study has several limitations. First, the observations of this study are tempered by the limitations inherent to crosssectional studies. Previous study suggest that cross-sectional studies underestimate true aging loss in muscle size and strength. 46 Second, we do not have the data of insulin resistance, therefore we evaluated the risk of type 2 diabetes mellitus only in HbA1c, which could be a common mechanism behind both sarcopenia and MetS. This point is also one of the limitations in this study.
CONCLUSION
The findings of the present study indicated that the coexistence of sarcopenia and MetS further increases the risks of CVD, such as type 2 diabetes mellitus, hypertension, arterial stiffness and hyperlipidemia even adjustment of age and body composition in adult Japanese women. It is important to prevent both sarcopenia and MetS for public health and to prevent the development of CVD.
